AnGes Inc
TSE:4563
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
J
|
Jet Airways (India) Ltd
NSE:JETAIRWAYS
|
IN |
|
JM Financial Ltd
NSE:JMFINANCIL
|
IN |
|
M
|
Mayur Uniquoters Ltd
NSE:MAYURUNIQ
|
IN |
|
Sleep Number Corp
NASDAQ:SNBR
|
US |
|
F
|
Frauenthal Holding AG
VSE:FKA
|
AT |
|
P
|
Pampa Energia SA
BCBA:PAMP
|
AR |
|
H
|
Hellenic Exchanges Athens Stock Exchange SA
ATHEX:EXAE
|
GR |
|
ILPRA SpA
MIL:ILP
|
IT |
|
Beijing GeoEnviron Engineering & Technology Inc
SSE:603588
|
CN |
|
Parity Group PLC
LSE:PTY
|
UK |
|
Xilam Animation SA
PAR:XIL
|
FR |
|
Zheng LI Holdings Ltd
HKEX:8283
|
SG |
|
N
|
Novo Nordisk A/S
LSE:0QIU
|
DK |
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| JP |
|
AnGes Inc
TSE:4563
|
23B JPY |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
365.4B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
184.6B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
173.9B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.3B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.7B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
67B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
39.6B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -122 700% |
| 30th Percentile | 2.9% |
| Median | 5.4% |
| 70th Percentile | 8.5% |
| Max | 63 031.4% |
Other Profitability Ratios
AnGes Inc
Glance View
AnGes, Inc. engages in the research and development of gene-based medical products. The company is headquartered in Ibaraki-Shi, Osaka-Fu and currently employs 131 full-time employees. The company went IPO on 2002-09-25. The firm is involved in the development of hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, among others. As of December 31, 2012, the Company had four consolidated subsidiaries. On January 31, 2013, the Company sold a 95.3% stake of a Osaka-based subsidiary to ISHIHARA SANGYO KAISHA LTD.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for AnGes Inc is -597.8%, which is above its 3-year median of -5 814.1%.
Over the last 3 years, AnGes Inc’s Net Margin has increased from -21 942.4% to -597.8%. During this period, it reached a low of -21 942.4% on Dec 31, 2022 and a high of -597.8% on Jan 1, 2026.
